Projects per year
Personal profile
Personal profile
Dr. Jagannath is a medical microbiologist with an MSC degree and received his PhD degree from Jawaharlal Institute of Postgraduate Medical Education and Research, University of Madras, Pondicherry, India in 1984. He was an assistant director of infectious disease under the Ministry health, Govt of India and relocated to USA in 1990. As an instructor at the University of Illinois, Chicago, between 1991-92, he published several papers on drugs for treating multi-drug resistant tuberculosis. In 1992, he relocated to CytRX corporation Atlanta continuing TB drug research and was an adjunct Associate Professor the Emory School of Medicine. In 1996, he joined the Dept. of Pathology and laboratory medicine UTHSC Houston as an Associate Professor retired as a tenured Professor in 2018. During 20 years of research at UTHSC, he pioneered the new generation autophagy-inducing vaccines for TB and his recombinant BCG85B vaccine RESEARCH published in Nature Medicine in 2009 was profiled on NIAID website. His lab published more than 80 publications (Hi index 39; i10-index 77; >12,000 citations; Google scholar) reporting novel findings in tuberculous pathogenesis and vaccine development using mouse models. During his tenure at UTHSC-Houston, he was a teaching member for the Program in Immunology at the Graduate School Biomedical Sciences and mentored seven MS/PhD students for their degree.
Professor Jagannath is now a member of the Houston Academic Institute and a faculty at Weill Cornell Medicine. Since Jan 2019, he has established a Tuberculosis vaccine and adjuvant research laboratory at the Dept. of Pathology and Genomic medicine, HMRI, Houston. He continues his vaccine research using mice, humanized mice, and nonhuman primate models for research. His current research is on understanding and strengthening of human immune responses to infections through a Systems Biology approach using human and NHP derived immune cells and models. His lab has received near continuous NIH RO1 grant funding since 2001. He continues to serve NIH study sections and was a past empaneled member of the CSR VMD study section.
Potential for graduate student research: Ongoing research thrust includes a Systems Biology approach for macrophage and dendritic cell activation for immunotherapy of human infections; augmenting tuberculosis vaccine responses; antibody mediated immunotherapy for tuberculosis, and vaccination strategies for infants. We are currently developing new generation, intradermal and mucosal vaccines for boosting BCG vaccines against tuberculosis using mouse and NHP models.
External positions
Professor of Pathology and Laboratory Medicine , Weill Cornell Medical College
Mar 1 2021 → …
Research Area Keywords
- Infectious Disease & Pathology
Free-text keywords
- Tuberculosis
- Vaccines
- Human immunology
- Macrophage Biology
- Adjuvants
- Mouse models
- Innate immunity
Fingerprint
- 1 Similar Profiles
Network
-
-
A Neonatal Monkey Model of Tuberculosis Vaccination
6/1/19 → 5/31/23
Project: Federal Funding Agencies
-
SigH based attenuated, efficacious Mtb vaccines to protect against lethal TB
5/1/19 → 4/30/23
Project: Federal Funding Agencies
-
Role of Metabolic Me-Macrophages in the Pathogenesis of Tuberculosis during Diabetes
3/1/21 → 2/28/23
Project: Federal Funding Agencies
-
Evaluation of immune responses to CD44-targeted nanovectors for designing a novel anti-tuberculosis host-directed therapy
Godin, B., Jagannath, C. & Leonard, F.
5/1/20 → 10/31/22
Project: Federal Funding Agencies
-
Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill Mycobacterium tuberculosis
Singh, V. K., Khan, A., Xu, Y., Mai, S., Zhang, L., Mishra, A., Restrepo, B. I., Pan, P. Y., Chen, S. H. & Jagannath, C., Jun 10 2022, In: Frontiers in immunology. 13, 865503.Research output: Contribution to journal › Article › peer-review
Open Access -
CD44 receptor targeted nanoparticles augment immunity against tuberculosis in mice
Singh, V. K., Chau, E., Mishra, A., DeAnda, A., Hegde, V. L., Sastry, J. K., Haviland, D., Jagannath, C., Godin, B. & Khan, A., Sep 2022, In: Journal of Controlled Release. 349, p. 796-811 16 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Emerging natural product based alternative therapeutics for tuberculosis
Singh, V. K., Mishra, A., Jagannath, C. & Khan, A., Jan 1 2022, Herbal Medicines: A Boon for Healthy Human Life. Elsevier, p. 453-471 19 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter
-
Human M1 macrophages express unique innate immune response genes after mycobacterial infection to defend against tuberculosis
Khan, A., Zhang, K., Singh, V. K., Mishra, A., Kachroo, P., Bing, T., Won, J. H., Mani, A., Papanna, R., Mann, L. K., Ledezma-Campos, E., Aguillon-Duran, G., Canaday, D. H., David, S. A., Restrepo, B. I., Viet, N. N., Phan, H., Graviss, E. A., Musser, J. M., Kaushal, D., & 2 others , May 19 2022, In: Communications Biology. 5, 1, 480.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Human Macrophages Exhibit GM-CSF Dependent Restriction of Mycobacterium tuberculosis Infection via Regulating Their Self-Survival, Differentiation and Metabolism
Mishra, A., Singh, V. K., Jagannath, C., Subbian, S., Restrepo, B. I., Gauduin, M. C. & Khan, A., May 12 2022, In: Frontiers in immunology. 13, 859116.Research output: Contribution to journal › Article › peer-review
Open Access